Nonalcoholic steatohepatitis (NASH) is a chronic yet silent disease, and patients present with few or no symptoms at early stages. The condition affects around 12% of the US population and there are currently no treatments available for those affected. NASH is also expected to be the leading cause of liver transplantation in the near future. …
One of the major challenges in oncology research today is the ability of tumors to evolve drug resistance. For researchers in the field, tackling cancer resistance can be a frustrating and somewhat unrewarding pursuit. During tumor progression, distinct cell populations with different molecular and phenotypic profiles start to form. The more heterogenous the tumor is …
Advances in gene therapies have provided opportunities to potentially correct the genetic abnormalities that lead to rare diseases, thereby offering a cure.
Fluorescence molecular imaging is the visualization of cellular and biological function in vivo to gain deeper insights into disease processes and treatment effects. Designing a more effective study requires careful consideration but can ultimately yield better and more meaningful results. The following steps will allow you to gain unique and meaningful biological information from your …
Developing new and effective treatments for rare diseases, which in the US are defined as those affecting fewer than 200,000 people, presents numerous challenges for researchers. The low prevalence and often heterogeneous nature of rare diseases means that there is often a considerable lack of scientific knowledge surrounding these conditions. Add to that the challenge …
The growing epidemics of obesity and type 2 diabetes have fueled an increasing prevalence of non-alcoholic fatty liver disease (NAFLD) across the globe, with around one quarter of US adults now affected.1 Many believe that NAFLD is yet to be widely recognized as a major public health challenge. For example, several liver disease experts recently …
Effective treatment options for the COVID-19 virus emerged from both currently marketed therapeutics, as well as from drugs in investigational discovery for the treatment of similar infectious diseases. The antiviral drug Remdesivir, under evaluation as an antiviral drug, was originally evaluated for the treatment of Ebola virus disease in 2014. In vitro Remdesivir studies highlighted …
As the global population is progressively becoming older, we are seeing an increase in the prevalence of neurological diseases. Many of these conditions disable patients long before they become fatal, meaning the burden of these diseases is likely to be huge in years to come. Despite vast amounts of research into neurological diseases, most cannot …
Developing drugs to target the central nervous system (CNS) is challenging as a result of the bloodbrain barrier (BBB) acting as an anatomical blockade, preventing many therapeutic candidates from reaching neuronal tissue directly. There are several models used in drug discovery to determine whether a therapeutic agent is fit for purpose in targeting neurological diseases. …
The use of immunotherapies to treat certain types of cancer has expanded greatly over the last 25 years. Today, there are many approved therapies that use immune checkpoint inhibitors to activate T-cell killing. Despite the successes, many patients are still found to be unresponsive to immunotherapy alone or develop resistance over time. Epigenetic therapy is …
